Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Ligand Pharmaceuticals has signed two deals under which it is selling its commercial drug portfolio to focus on its research efforts. Ligand is selling U.S. and Canadian rights to its morphine sulfate pain therapy Avinza to King Pharmaceuticals for $313 million. King will make unspecified royalty payments until Avinza's patent expires in 2017. Ligand also agreed to sell its oncology product line to Eisai for $205 million. Eisai will make royalty payments as well.
This article has been sent to the following recipient: